直肠癌初始M分期:FDG PET/MRI联合肝细胞特异性对比剂与增强CT的比较
前瞻性研究纳入71例新诊断的中低位进展期直肠癌患者,比较FDG PET/MRI(含专用肝脏和直肠MRI)与胸部及腹盆增强CT加专用直肠MRI的M分期效能,以6个月临床随访或活检为参考标准。标准方案因不确定病灶有31%无法确定M分期,而PET/MRI特异性排除转移达98%高于标准方案的72%,且未增加漏诊转移人数。
要点
- 标准方案(增强CT加直肠MRI)有31%患者因不确定病灶无法确定M分期
- PET/MRI在标准方案无法分期的患者中正确识别全部14例无转移和7/8例有转移
- PET/MRI排除转移特异性98%高于标准方案的72%,漏诊转移均为6%
核心结论
- FDG PET/MRI联合专用肝脏和直肠MRI通过更好地评估不确定病灶、转移和偶发发现,有助于新诊断进展期直肠癌的分期检查,避免额外的影像学检查。
研究设计与样本
- 前瞻性研究,2016年1月至2017年8月招募新诊断的进展期中低位直肠癌患者,共71例(女性28例,平均年龄61岁±9,范围39-79岁)。
- 参与者均在3周内接受FDG PET/MRI(含专用肝脏和直肠MRI)与胸部及腹盆增强CT(标准诊疗方案)及专用直肠MRI。
- 以6个月临床随访或活检结果为参考标准判定M分期评估效能,并比较两种方案间M分期分类的一致性。
- 采用非参数统计分析,P < .05表示差异有统计学意义;临床试验注册号NCT02651701。
诊断标准与关键数值
- 标准方案在71例中22例(31%;95%CI:20.5%,43.1%)因不确定病灶无法确定M分期。
- 在标准方案无法分期的22例中,PET/MRI正确识别全部14例(100%;95%CI:76.8%,100%)无转移者和8例中7例(88%;95%CI:47.4%,99.7%)后来 confirmed 有转移者。
- PET/MRI排除转移特异性98%(54/55)高于标准方案72%(40/55),P < .001。
- 漏诊转移比例PET/MRI 6%(1/16)与标准方案6%(1/16)无显著差异,P > .99。
临床应用与阅片要点
- 对于标准增强CT加直肠MRI因不确定病灶无法确定M分期的患者,PET/MRI可帮助明确有无转移。
- PET/MRI联合专用肝脏和直肠MRI可辅助评估不确定病灶、转移和偶发发现,避免额外影像学检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundThe performance of PET/MRI in the determination of distant metastases (M stage) in rectal cancer relative to the current practice with contrast material-enhanced CT is largely unknown.PurposeTo compare the staging of clinical M stage rectal cancer with fluorine 18 fluorodeoxyglucose (FDG) PET/MRI (including dedicated liver and rectal MRI) to that of chest and abdominopelvic CT and dedicated rectal MRI.Materials and MethodsFrom January 2016 to August 2017, patients with newly diagnosed advanced mid to low rectal cancers were recruited for this prospective study (clinicaltrials.gov identifier: NCT0265170). Participants underwent both FDG PET/MRI with dedicated liver and rectal MRI and chest and abdominopelvic CT (the standard-of-care protocol) within 3 weeks of each other. Thereafter, M stage assessment performance was determined by using findings from 6-month clinical follow-up or biopsy as the reference standard. Performance was compared between protocols. Agreement in M stage classification was also assessed. Nonparametric statistical analyses were performed, and P < .05 indicated a significance difference.ResultsSeventy-one participants (28 women; mean age ± standard deviation, 61 years ± 9; age range, 39-79 years) were enrolled. The M stage could not be determined with the standard-of-care protocol in 22 of the 71 participants (31%; 95% confidence interval [CI]: 20.5%, 43.1%) because of indeterminate lesions. However, among these participants, PET/MRI correctly helped identify all 14 (100%; 95% CI: 76.8%, 100%) without metastases and seven of eight (88%; 95% CI: 47.4%, 99.7%) who were later confirmed to have metastases. PET/MRI showed high specificity for ruling out metastatic disease compared with the standard-of-care protocol (98% [54 of 55 participants] vs 72% [40 of 55 participants], respectively; P < .001), without increasing the number of participants with missed metastasis (6% [one of 16 participants] vs 6% [one of 16 participants]; P > .99).ConclusionPET/MRI with dedicated rectal and liver MRI can facilitate the staging work-up of newly diagnosed advanced rectal cancers by helping assess indeterminate lesions, metastases, and incidental findings better than contrast-enhanced CT, obviating for additional imaging work-up.© RSNA, 2019Online supplemental material is available for this article.Clinical trial registration no. NCT02651701.
引用
- Yoon JH, Lee JM, Chang W, et al. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT. Radiology. 2019. PMID: 31793850. doi:10.1148/radiol.2019190794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。